Trial Profile
Prospective trial to assess melanoma antigens as biomarker for ipilimumab response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 31 May 2017 New trial record